NEW YORK, July 1, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA).
To receive updates on the lawsuit, fill out the form:
The lawsuit seeks to recover losses for shareholders who purchased Verrica between May 28, 2021 and May 24, 2022.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until August 5, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Verrica Pharmaceuticals, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original content:
SOURCE Jakubowitz Law